Therapeutic vaccines have been developed to aid in the healing process of various diseases and illnesses. The vaccines have helped to lessen the severity of the illness or disease, and have even helped to prevent diseases from recurring. It is important to note that some of the most effective and potent vaccines are derived from living viruses such as the hepatitis B virus and the poliovirus. However, since these are living organisms, they require a host to grow inside the host and provoke the needed immune response.
Market Dynamics
High prevalence of cancer and other chronic disorders is expected to propel growth of the therapeutic vaccines market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Emergence of Covid-19 is expected to offer lucrative growth opportunities for players in the therapeutic vaccines market. For instance, in August 2020, GeneCure Biotechnologies, a clinical stage biotechnology company, launched a therapeutic vaccine program for Covid-19 infection.
Moreover, R&D of new vaccines is also expected to aid in growth of the market. For instance, in October 2020, researchers from the Institute of Process Engineering (IPE) of Chinese Academy of Sciences and Zhujiang Hospital of Southern Medical University reported development of a new type of precise therapeutic vaccine against leukemia, in Nature Biomedical Engineering. Similarly, in February 2020, IO Biotech, a clinical-stage biopharmaceutical company, announced the successful outcome of a scheduled interim analysis of the ongoing phase 2 trial (IO102-012/KEYNOTE-764) of its lead cancer therapeutic vaccine, IO102, in non-small cell lung cancer (NSCLC).
Among regions, North America is expected to witness significant growth in the therapeutic vaccines market, owing to high prevalence of Alzheimer’s disease. For instance, according to Alzheimer’s Association, around 5.8 million people in the U.S. aged 65 and older are living with Alzheimer's dementia in 2020.
Competitive Analysis
Major players operating in the therapeutic vaccines market include, Novartis AG, GlaxoSmithKline, Pfizer, Inc., Cytos Biotechnology AG, Alzinova AB, Argos Therapeutic Inc., Merck & Co., Dendreon Corp, Bavarian Nordic A/S, and Agenus, Inc.
Major players operating in the therapeutic vaccines market are focused on R&D to expand their product portfolio. For instance, in November 2020, Alzinova AB announced the upcoming clinical study with the vaccine candidate ALZ-101 at the scientific congress Clinical Trials in Alzheimer's Disease. The planned study will be conducted in patients with early Alzheimer's disease and is expected to commence during the second quarter 2021.
No comments:
Post a Comment